InsiderTrades.com logo
Is Starlink Set For The Largest IPO In History?
From Paradigm Press   |   Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!
Click here now for the urgent details.
Andrew S. Boyer net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Andrew Boyer Biography and Net Worth

EVP, Chief Commercial Officer – Generics of Amneal Pharmaceuticals
Andy is focused on accelerating the sales, marketing and distribution of our evolving generics portfolio. Andy most recently served as President and CEO of North America Generics, Teva Pharmaceuticals, Inc. Prior to joining Teva, Andy was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan plc (formerly, Actavis plc; formerly, Watson Pharmaceuticals, Inc.) since September 2006. He joined then Watson in 1998 as Associate Director of Marketing in Generics. Before joining Watson, Andy served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines. Andy received his Bachelor’s degree in Business Administration and Management from State University of New York at Albany.

What is Andrew S. Boyer's net worth?

The estimated net worth of Andrew S. Boyer is at least $1.90 million as of August 11th, 2023. Mr. Boyer owns 244,739 shares of Amneal Pharmaceuticals stock worth more than $1,904,069 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Boyer may own. Additionally, Mr. Boyer receives a salary of $1,200,000.00 as EVP, Chief Commercial Officer – Generics at Amneal Pharmaceuticals. Learn More about Andrew S. Boyer's net worth.

How old is Andrew S. Boyer?

Mr. Boyer is currently 58 years old. There are 5 older executives and no younger executives at Amneal Pharmaceuticals. Learn More on Andrew S. Boyer's age.

What is Andrew S. Boyer's salary?

As the EVP, Chief Commercial Officer – Generics of Amneal Pharmaceuticals, Inc., Mr. Boyer earns $1,200,000.00 per year. There are 2 executives that earn more than Mr. Boyer. The highest earning executive at Amneal Pharmaceuticals is Mr. Chirag K. Patel, Co-Founder, Co-CEO, President & Director, who commands a salary of $1,710,000.00 per year. Learn More on Andrew S. Boyer's salary.

How do I contact Andrew S. Boyer?

The corporate mailing address for Mr. Boyer and other Amneal Pharmaceuticals executives is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807, United States. Amneal Pharmaceuticals can also be reached via phone at 908-947-3120 and via email at [email protected]. Learn More on Andrew S. Boyer's contact information.

Has Andrew S. Boyer been buying or selling shares of Amneal Pharmaceuticals?

Andrew S. Boyer has not been actively trading shares of Amneal Pharmaceuticals during the past quarter. Most recently, Andrew S. Boyer sold 29,302 shares of the business's stock in a transaction on Friday, August 11th. The shares were sold at an average price of $4.13, for a transaction totalling $121,017.26. Following the completion of the sale, the executive vice president now directly owns 244,739 shares of the company's stock, valued at $1,010,772.07. Learn More on Andrew S. Boyer's trading history.

Who are Amneal Pharmaceuticals' active insiders?

Amneal Pharmaceuticals' insider roster includes Andrew Boyer (EVP, Chief Commercial Officer – Generics), Chirag Patel (Co-Founder, Co-CEO, President & Director), Gautam Patel (Director), Nikita Shah (EVP), and Joseph Todisco (EVP). Learn More on Amneal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amneal Pharmaceuticals?

During the last year, insiders at the sold shares 1 times. They sold a total of 43,657 shares worth more than $375,886.77. The most recent insider tranaction occured on November, 15th when SVP Jason B Daly sold 43,657 shares worth more than $375,886.77. Insiders at Amneal Pharmaceuticals own 26.6% of the company. Learn More about insider trades at Amneal Pharmaceuticals.

Information on this page was last updated on 11/15/2024.

Andrew S. Boyer Insider Trading History at Amneal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2023Sell29,302$4.13$121,017.26244,739View SEC Filing Icon  
8/7/2019Buy66,666$2.89$192,664.74View SEC Filing Icon  
5/13/2019Buy19,000$9.46$179,740.00View SEC Filing Icon  
See Full Table

Andrew S. Boyer Buying and Selling Activity at Amneal Pharmaceuticals

This chart shows Andrew S Boyer's buying and selling at Amneal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amneal Pharmaceuticals Company Overview

Amneal Pharmaceuticals logo
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Read More

Today's Range

Now: $7.78
Low: $7.57
High: $7.86

50 Day Range

MA: $8.42
Low: $7.69
High: $9.25

2 Week Range

Now: $7.78
Low: $5.01
High: $9.48

Volume

1,657,823 shs

Average Volume

1,382,215 shs

Market Capitalization

$2.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12
Is Starlink Set For The Largest IPO In History?
From Paradigm Press   |   Ad
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!
Click here now for the urgent details.